Literature DB >> 23579796

Nitric oxide production by Peromyscus yucatanicus (Rodentia) infected with Leishmania (Leishmania) mexicana.

Elsy Nalleli Loría-Cervera1, Erika Ivett Sosa-Bibiano, Liliana Estefanía Villanueva-Lizama, Nicole Raymonde Van Wynsberghe, Silvia Beatriz Canto-Lara, José Luis Batún-Cutz, Fernando José Andrade-Narváez.   

Abstract

Peromyscus yucatanicus (Rodentia: Cricetidae) is a primary reservoir of Leishmania (Leishmania) mexicana (Kinetoplastida: Trypanosomatidae). Nitric oxide (NO) generally plays a crucial role in the containment and elimination of Leishmania. The aim of this study was to determine the amount of NO produced by P. yucatanicus infected with L. (L.) mexicana. Subclinical and clinical infections were established in P. yucatanicus through inoculation with 1 x 10 2 and 2.5 x 10 6 promastigotes, respectively. Peritoneal macrophages were cultured alone or co-cultured with lymphocytes with or without soluble Leishmania antigen. The level of NO production was determined using the Griess reaction. The amount of NO produced was significantly higher (p ≤ 0.0001) in co-cultured macrophages and lymphocytes than in macrophages cultured alone. No differences in NO production were found between P. yucatanicus with subclinical L. (L.) mexicana infections and animals with clinical infections. These results support the hypothesis that the immunological mechanisms of NO production in P. yucatanicus are similar to those described in mouse models of leishmaniasis and, despite NO production, P. yucatanicus is unable to clear the parasite infection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23579796      PMCID: PMC3970676          DOI: 10.1590/0074-0276108022013008

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  34 in total

1.  Lymphocytes of dogs immunised with purified excreted-secreted antigens of Leishmania infantum co-incubated with Leishmania infected macrophages produce IFN gamma resulting in nitric oxide-mediated amastigote apoptosis.

Authors:  P Holzmuller; M Cavaleyra; J Moreaux; R Kovacic; P Vincendeau; G Papierok; J-L Lemesre
Journal:  Vet Immunol Immunopathol       Date:  2005-07-15       Impact factor: 2.046

Review 2.  Immunological factors governing resistance and susceptibility of mice to Leishmania major infection.

Authors:  F Aguilar-Torrentera; Y Carlier
Journal:  Rev Latinoam Microbiol       Date:  2001 Jul-Sep

3.  Leishmania amazonensis infections in Oryzomys acritus and Oryzomys nitidus from Bolivia.

Authors:  Sara F Kerr; Louise H Emmons; Peter C Melby; Chang Liu; Luis E Perez; Maria Villegas; Robert Miranda
Journal:  Am J Trop Med Hyg       Date:  2006-12       Impact factor: 2.345

4.  DNA vaccines induce partial protection against Leishmania mexicana.

Authors:  Eric Dumonteil; Ramirez Sierra Maria Jesus; Escobedo Ortegon Javier; García Miss Maria del Rosario
Journal:  Vaccine       Date:  2003-05-16       Impact factor: 3.641

5.  Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes.

Authors:  Jean-Loup Lemesre; Philippe Holzmuller; Mireille Cavaleyra; Rachel Bras Gonçalves; Grégory Hottin; Gérard Papierok
Journal:  Vaccine       Date:  2005-04-22       Impact factor: 3.641

6.  Use of monoclonal antibodies for the identification of Leishmania spp. isolated from humans and wild rodents in the State of Campeche, Mexico.

Authors:  S B Canto-Lara; N R Van Wynsberghe; A Vargas-González; F F Ojeda-Farfán; F J Andrade-Narváez
Journal:  Mem Inst Oswaldo Cruz       Date:  1999 May-Jun       Impact factor: 2.743

Review 7.  Canine leishmaniasis.

Authors:  Jorge Alvar; Carmen Cañavate; Ricardo Molina; Javier Moreno; Javier Nieto
Journal:  Adv Parasitol       Date:  2004       Impact factor: 3.870

8.  Interferon-gamma is required for the late but not early control of Leishmania amazonensis infection in C57Bl/6 mice.

Authors:  Roberta Olmo Pinheiro; Bartira Rossi-Bergmann
Journal:  Mem Inst Oswaldo Cruz       Date:  2007-02       Impact factor: 2.743

9.  First encounter of subclinical human Leishmania (Viannia) infection in State of Rio Grande do Sul, Brazil.

Authors:  Aline Fagundes; Mauro C A Marzochi; Octavio Fernandes; Mauricio A Perez; Armando O Schubach; Tânia M P Schubach; Maria R R Amendoeira; Eliame Mouta-Confort; Keyla B F Marzochi
Journal:  Mem Inst Oswaldo Cruz       Date:  2007-12       Impact factor: 2.743

10.  Seasonal transmission of Leishmania (Leishmania) mexicana in the state of Campeche, Yucatan Peninsula, Mexico.

Authors:  Fernando J Andrade-Narvaez; Silvia B Canto Lara; Nicole R Van Wynsberghe; Eduardo A Rebollar-Tellez; Alberto Vargas-Gonzalez; Nelly E Albertos-Alpuche
Journal:  Mem Inst Oswaldo Cruz       Date:  2003-12       Impact factor: 2.743

View more
  3 in total

Review 1.  Animal models for the study of leishmaniasis immunology.

Authors:  Elsy Nalleli Loría-Cervera; Fernando José Andrade-Narváez
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2014 Jan-Feb       Impact factor: 1.846

2.  In Vitro Antileishmanial Activity of Essential Oil of Vanillosmopsis arborea (Asteraceae) Baker.

Authors:  Aracélio Viana Colares; Fernando Almeida-Souza; Noemi Nosomi Taniwaki; Celeste da Silva Freitas Souza; José Galberto Martins da Costa; Kátia da Silva Calabrese; Ana Lúcia Abreu-Silva
Journal:  Evid Based Complement Alternat Med       Date:  2013-07-09       Impact factor: 2.629

3.  Combined therapy with adipose tissue-derived mesenchymal stromal cells and meglumine antimoniate controls lesion development and parasite load in murine cutaneous leishmaniasis caused by Leishmania amazonensis.

Authors:  Tadeu Diniz Ramos; Johnatas Dutra Silva; Alessandra Marcia da Fonseca-Martins; Juliana Elena da Silveira Pratti; Luan Firmino-Cruz; Diogo Maciel-Oliveira; Julio Souza Dos-Santos; João Ivo Nunes Tenorio; Almair Ferreira de Araujo; Célio Geraldo Freire-de-Lima; Bruno Lourenço Diaz; Fernanda Ferreira Cruz; Patricia Rieken Macedo Rocco; Herbert Leonel de Matos Guedes
Journal:  Stem Cell Res Ther       Date:  2020-08-31       Impact factor: 6.832

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.